However, there are no aptamers currently approved for cancer therapy, probably due to their rapid clearance, and only two aptamers (AS1411 against nucleolin and NOX-A12 against CXCL12) are in clinical trials for cancer therapy [43,64]. This evidence concerns the gene CXCL12 and cancer.